摘要
目的评价CEA、NSE、CYFRA21-1联合检测对肺癌与良性肺部疾病鉴别诊断的价值。方法应用电化学发光法(ECLIA)检测经病理确诊的56例肺癌、41例良性肺部疾病和30例正常体检者血清中癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)和细胞角蛋白21-1(CYFRA21-1)的含量。结果肺癌组CEA、NSE、CYFRA21-1测定水平明显高于肺良性病变组和正常对照组,差异具有统计学意义(P<0.05);CEA、NSE、CYFRA21-1对肺癌的敏感性分别为51.79%、44.64%、55.36%,特异性分别为92.96%、90.14%、88.73%;CEA、NSE、CYFRA21-1三项联合检测对肺癌的敏感性与特异性分别为92.86%和94.37%。结论CEA、NSE、CYFRA21-1三项肿瘤标记物联合检测明显提高肺癌诊断的阳性率,有助于肺癌的预测和鉴别诊断。
Objective To explore the clinical application of serum CEA, NSE and CYFRA21-1 markers in diagnosis of patients with lung cancer. Method Serum levels of CEA, NSE and CYFRA21-1 were determined by electrochemiluminescence （ECLIA） in 56 patients with lung cancer, 41 patients with benign lungs diseases and 30 normal subjects. Result The serum levels of CEA, NSE and CYFRA21-1 were markedly elevated in patients with lung cancer than those with benign lung diseases and healthy subjects （P〈0.05）.The sensitivity of CEA, NSE and CYFRA21-1 for the lung cancer was 51.79%, 44.64% and 55.36%, and the specificity were 92.96%,90.14% and 88.73%, respectively. The sensitivity and specificity of combined detection of these three tumor markers were 92.86% and 94.37%, respectively. Conclusion Combined detection of serum CEA, NSE and CYFRA21-1 could significantly improve the sensitivity of diagnosis of lung cancer. These markers can also be used in the disease prediction.
出处
《热带医学杂志》
CAS
2009年第8期941-942,953,共3页
Journal of Tropical Medicine
基金
广东省自然科学基金(No.07300312
8451051501000580)
